Liquid Biopsy

Liquid Biopsy Market Outlook

The global liquid biopsy market is poised for significant growth, projected to reach USD 6.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2035. This promising growth trajectory is primarily fueled by the increasing prevalence of cancer worldwide, coupled with the shift towards non-invasive diagnostic approaches that offer greater patient convenience and faster results. Additionally, advancements in technology, including next-generation sequencing (NGS) and digital PCR, are enhancing the sensitivity and specificity of liquid biopsy tests, further driving market adoption. As healthcare systems continue to focus on personalized medicine, the demand for liquid biopsies as a tool for targeted therapy selection is expected to rise dramatically. Furthermore, the growing investments in research and development (R&D) aimed at discovering new biomarkers and improving existing techniques contribute to a robust market ecosystem.

Growth Factor of the Market

One of the primary growth factors for the liquid biopsy market is the increasing incidences of various cancers, which necessitate innovative diagnostic tools for timely detection and monitoring. The growing awareness about early cancer diagnosis among the global population is also playing a pivotal role in boosting market growth. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, thereby reducing patient discomfort and complications associated with surgical procedures. Additionally, the rising emphasis on personalized medicine has led to a surge in demand for liquid biopsies, as these tests provide valuable insights into tumor biology, enabling tailored treatment approaches. Moreover, the proliferation of advanced technologies in molecular diagnostics, including the integration of artificial intelligence (AI) and machine learning, is enhancing the analytical capabilities of liquid biopsies, making them a preferred choice for healthcare professionals.

Key Highlights of the Market

• Significant market growth expected with a CAGR of 15.3% from 2025 to 2035.
• Increasing prevalence of cancer is driving demand for liquid biopsy tests.
• Technological advancements are improving the accuracy and efficiency of tests.
• Growing shift towards personalized medicine is enhancing the relevance of liquid biopsies.
• Non-invasive nature of liquid biopsies is increasing their adoption in clinical practice.

By Product Type

CTC-CTDNA Assays:

Circulating Tumor Cell (CTC) and Circulating Tumor DNA (ctDNA) assays represent a pivotal segment within the liquid biopsy market. These assays allow for the detection and analysis of tumor-specific genetic material shed into the bloodstream, providing critical insights into tumor behavior and treatment responsiveness. The ability to identify mutations and alterations in real time empowers physicians to customize treatment plans, thereby improving patient outcomes. Furthermore, advancements in NGS technology have significantly enhanced the sensitivity of these assays, enabling the detection of minimal residual disease (MRD) and monitoring of therapeutic efficacy over time. As more studies validate the clinical utility of CTC-ctDNA assays, their use in routine clinical practice is expected to grow, solidifying their position in the market.

Circulating Tumor Cell Assays:

Circulating Tumor Cell assays focus specifically on isolating and analyzing tumor cells that circulate in the peripheral blood. This product type is crucial for understanding tumor dynamics and heterogeneity. The ability to monitor CTC counts and characteristics offers valuable prognostic information for various cancer types. Additionally, the development of innovative technologies, such as microfluidics and immunoaffinity capture methods, has improved the efficiency of CTC isolation and characterization. As researchers continue to investigate CTCs for their potential to predict treatment responses and disease progression, the market for these assays is anticipated to expand significantly in the coming years.

Exosome Diagnostics:

Exosome diagnostics is a rapidly evolving area within the liquid biopsy market. Exosomes are nanosized vesicles released by cells that contain a cargo of proteins, lipids, and nucleic acids reflective of their originating cells. This characteristic makes them valuable for biomarker discovery and disease monitoring. The non-invasive collection of exosomes from bodily fluids such as blood and urine presents a unique opportunity for researchers and clinicians. As technologies for exosome isolation and analysis improve, their application in oncology—ranging from early detection to monitoring therapeutic responses—will likely play a significant role in shaping the future of liquid biopsies.

Others:

The 'Others' category in product types captures various innovative solutions and emerging technologies in the liquid biopsy space, which may include multi-omics approaches, advanced imaging techniques, and novel biomarkers. This segment is characterized by a broad range of research and experimental methods that are still in development or early commercialization stages. Innovations in this area could lead to significant breakthroughs in cancer diagnostics and personalized treatment strategies. The continuous exploration of diverse products in the liquid biopsy domain highlights the dynamic nature of the market and the potential for future growth driven by novel discoveries.

By Application

Early Cancer Screening:

Early cancer screening is one of the most critical applications of liquid biopsy, as timely detection can significantly improve treatment outcomes and survival rates. Liquid biopsies provide a non-invasive method to identify cancer at an early stage by detecting specific biomarkers associated with tumor presence. This application is particularly valuable for cancers that are typically diagnosed at advanced stages, such as pancreatic and ovarian cancer. The growing focus on preventive healthcare and routine screening is further propelling the adoption of liquid biopsy tests for early diagnosis, paving the way for improved patient prognoses and reduced healthcare costs associated with advanced cancer treatments.

Therapy Selection:

Therapy selection through liquid biopsy tests is instrumental in the era of personalized medicine, where treatments are tailored to individual patient profiles. Liquid biopsies allow for the identification of actionable mutations and biomarkers that can guide oncologists in selecting the most appropriate therapies for their patients. This application is particularly relevant in the context of targeted therapies and immunotherapies, where the efficacy of treatment may depend on specific genetic alterations. By enabling real-time monitoring of tumor evolution and response to treatment, liquid biopsies empower healthcare providers to make informed decisions, optimizing patient outcomes and minimizing the potential for adverse effects.

Treatment Monitoring:

Treatment monitoring is a vital application of liquid biopsies, offering a non-invasive means to evaluate therapeutic effectiveness. This aspect of liquid biopsy allows clinicians to track changes in tumor burden, genetic mutations, and resistance mechanisms during treatment, providing insights into disease progression or regression. By obtaining frequent blood samples, healthcare providers can make timely adjustments to treatment regimens based on the latest findings from liquid biopsy tests. This capability helps enhance patient management, reduces the need for invasive procedures, and contributes to more effective treatment strategies.

Recurrence Monitoring:

Recurrence monitoring is an essential application of liquid biopsy that focuses on identifying minimal residual disease (MRD) and detecting cancer recurrence post-treatment. Liquid biopsies provide a sensitive method for assessing the presence of circulating tumor DNA, CTCs, or other biomarkers indicative of relapse. This proactive approach enables clinicians to intervene early, potentially improving outcomes for patients who may otherwise experience a delay in detection. The shifting paradigm toward monitoring patients after initial therapy underscores the importance of liquid biopsies in ensuring long-term survival and quality of life.

Others:

The 'Others' category in applications encompasses various exploratory uses of liquid biopsy beyond the primary applications of screening, therapy selection, treatment monitoring, and recurrence detection. This may include applications in immuno-oncology, drug resistance profiling, and research-focused studies investigating the role of liquid biopsies in different cancer types and stages. As research continues to unveil the myriad possibilities for liquid biopsy applications, this segment is expected to experience growth as innovative solutions emerge and gain traction in clinical practice.

By Sample Type

Blood:

Blood represents the most commonly used sample type in liquid biopsy applications. Its ease of collection and rich information content, including circulating tumor cells, ctDNA, and exosomes, make it an ideal candidate for cancer diagnostics and monitoring. The ability to perform repeat sampling without significant patient discomfort allows for ongoing assessment of tumor dynamics and treatment responses. As technology advances, the sensitivity and specificity of blood-based liquid biopsies continue to improve, reinforcing their role as essential tools in oncology, particularly for early detection and recurrence monitoring.

Urine:

Urine is emerging as a valuable sample type for liquid biopsy due to its non-invasive nature and the presence of various biomarkers related to cancer. Urinary biomarkers can provide unique insights into tumor biology and are particularly relevant for cancers of the urinary tract, such as bladder cancer. The simplicity of urine collection makes it an attractive option for routine screening and monitoring, increasing patient compliance. Advances in urine-based liquid biopsy technologies are expected to expand the applications of this sample type in cancer diagnostics, contributing to the overall growth of the market.

Other Body Fluids:

Other body fluids, including pleural fluid, ascitic fluid, and cerebrospinal fluid, are gaining attention in the liquid biopsy landscape for their potential to provide valuable diagnostic information. These fluids may contain cell-free DNA, exosomes, and other biomarkers that can inform clinicians about tumor characteristics and disease progression. While less commonly used than blood and urine, the analysis of these body fluids can offer critical insights, especially in advanced cancer stages where traditional biopsy methods may be challenging. Research and development in this area are ongoing, with the potential to broaden the scope of liquid biopsy applications.

By Biomarker Type

CTCs:

Circulating Tumor Cells (CTCs) are a focal point in the liquid biopsy market as they represent viable tumor cells that have detached from the primary tumor and entered the bloodstream. The analysis of CTCs provides crucial information regarding tumor heterogeneity, metastasis, and treatment response. Technologies for isolating and characterizing CTCs have advanced significantly, leading to improved understanding of their role in cancer progression. As research continues to validate the clinical utility of CTCs, their integration into routine diagnostics and monitoring is expected to enhance patient management strategies and outcomes.

Circulating DNA:

Circulating tumor DNA (ctDNA) has emerged as a critical biomarker in the liquid biopsy field, representing fragments of DNA shed by tumors into the bloodstream. The analysis of ctDNA enables the detection of specific mutations, providing insights into tumor genetics and guiding treatment decisions. ctDNA is particularly valuable in monitoring treatment response and detecting resistance mutations over time, allowing for timely adjustments to therapeutic strategies. The growing recognition of ctDNA's significance in oncology is driving research and development efforts, positioning it as a cornerstone of modern cancer diagnostics.

Exosomes:

Exosomes are nanoscale extracellular vesicles that carry a diverse array of biomolecules, including proteins, lipids, and RNA, reflective of their cell of origin. As a biomarker type, exosomes are gaining prominence in liquid biopsy applications due to their potential for providing insights into tumor microenvironments and intercellular communication. The analysis of exosomes can offer valuable information regarding tumor behavior, immune responses, and treatment effects. With continued advancements in isolation and characterization techniques, exosomes are expected to play an increasingly important role in the future of cancer diagnostics.

Others:

The 'Others' category in biomarker types includes a range of emerging markers and novel approaches being explored in liquid biopsy research. This may encompass various cell-free biomarkers, such as RNA species and metabolites, which could provide additional layers of information regarding tumor biology and patient responses to therapy. As ongoing research uncovers new biomarker candidates and validates their clinical relevance, this segment is anticipated to grow, further enriching the liquid biopsy landscape.

By User

Hospitals:

Hospitals are a major user segment in the liquid biopsy market, as they serve as primary centers for cancer diagnosis and treatment. The incorporation of liquid biopsy tests into hospital settings allows for timely patient monitoring and decision-making, enhancing the overall quality of cancer care. With the growing emphasis on personalized medicine, hospitals are increasingly adopting liquid biopsy technologies for routine testing and follow-up assessments. The ability to offer non-invasive testing options aligns with hospital goals to improve patient experiences while optimizing resource utilization.

Diagnostic Laboratories:

Diagnostic laboratories are crucial players in the liquid biopsy value chain, responsible for processing and analyzing samples to provide insights into cancer diagnosis and prognosis. These laboratories are at the forefront of technological advancements, adopting the latest methods in liquid biopsy to deliver accurate and timely results. The increasing demand for liquid biopsy tests is driving expansion within diagnostic labs, leading to enhanced capabilities and the adoption of automated systems to streamline workflows. The collaboration between diagnostic labs and healthcare providers is facilitating the integration of liquid biopsy into standard care protocols.

Academic Research Centers:

Academic research centers play an instrumental role in the liquid biopsy market by driving innovation and discovery. These institutions are often involved in extensive research efforts to explore new biomarkers, refine liquid biopsy technologies, and validate clinical applications. The collaboration between academia and industry fosters an environment for translating research findings into clinical practice. As liquid biopsy continues to evolve, academic research centers are expected to remain at the forefront of exploring novel applications and enhancing the understanding of tumor biology through non-invasive methods.

Others:

The 'Others' category in the user segment encompasses a range of entities that utilize liquid biopsy technologies, including biotechnology firms, pharmaceutical companies, and contract research organizations (CROs). This diverse group is involved in various aspects of the liquid biopsy ecosystem, from developing new diagnostic tools to conducting clinical trials and research studies. The growing interest in liquid biopsies from these entities indicates a robust market landscape, with potential collaborations and partnerships driving further advancements in technology and applications.

By Region

The North America region is expected to dominate the liquid biopsy market, accounting for approximately 40% of the global market share by 2035. This can be attributed to the established healthcare infrastructure, high prevalence of cancer, and substantial investments in research and development activities. The presence of leading biotech and pharmaceutical companies in the region, coupled with favorable government initiatives aimed at promoting innovation in cancer diagnostics, further enhances North America's market position. Furthermore, the growing awareness among healthcare professionals and patients regarding the advantages of liquid biopsies is expected to drive sustained growth in this region.

Europe is projected to be the second-largest market for liquid biopsies, contributing around 30% to the global market by 2035. The region benefits from a robust healthcare system and a rising focus on precision medicine, which is fostering the adoption of liquid biopsy technologies. Countries such as Germany, France, and the UK are leading the way in terms of research and implementation of liquid biopsy applications. The growing collaborations between academic institutions and industry players in Europe are also expected to accelerate advancements in liquid biopsy research and commercialization. Notably, the Asia Pacific region is anticipated to witness the highest CAGR of 18.4% during the forecast period, driven by increasing cancer incidences, rising healthcare expenditure, and a growing emphasis on personalized treatment approaches.

Opportunities

The liquid biopsy market presents substantial opportunities for growth and innovation, particularly in the realm of technological advancements and the development of new biomarkers. As research progresses, there is a growing potential for liquid biopsy applications to expand beyond oncology into other areas such as infectious diseases and chronic conditions, broadening the market scope. Companies investing strategically in R&D will have the opportunity to pioneer novel liquid biopsy platforms that enhance sensitivity, specificity, and overall clinical utility. Additionally, as regulatory frameworks adapt to the burgeoning field of liquid biopsies, streamlined approval processes may facilitate quicker market entry for new products and solutions. This creates an inviting landscape for startups and established players alike, fostering a competitive ecosystem that thrives on innovation.

Moreover, the rising trend towards home healthcare and point-of-care testing creates unique opportunities for liquid biopsy technologies to become integrated into everyday clinical practice. The convenience of non-invasive sampling methods aligns well with patient preferences for less invasive procedures, promoting higher adoption rates. With an increase in the number of collaborations between technology developers and healthcare providers, there is potential for the creation of comprehensive liquid biopsy solutions that improve patient management and outcomes. The evolving landscape of artificial intelligence and machine learning also offers promising avenues for integrating data analytics with liquid biopsies, enabling personalized insights that enhance decision-making processes in oncology.

Threats

Despite the positive outlook for the liquid biopsy market, there are significant threats that could impede its growth trajectory. One of the primary concerns is the potential for regulatory hurdles and uncertainty surrounding the approval processes for liquid biopsy tests. As the field evolves rapidly, regulatory agencies may struggle to keep pace with technological developments, leading to delays in product approvals and market entry. Additionally, the lack of standardized protocols for liquid biopsy testing can result in variability in results and interpretations, raising questions about the reliability of these tests in clinical settings. Such issues may hinder widespread adoption and acceptance among healthcare professionals, ultimately affecting market growth.

Another major threat to the liquid biopsy market is the competitive landscape, which is becoming increasingly crowded with both established players and new entrants. As more companies invest in liquid biopsy technologies, the competition for market share will intensify, potentially leading to price wars and reduced profit margins. Furthermore, the ongoing advancements in traditional biopsy techniques and imaging modalities could overshadow the benefits of liquid biopsies, particularly in oncology, where physicians may prefer established methods for diagnosis and monitoring. These factors create an environment of uncertainty that could challenge the liquid biopsy market's expansion and sustainability in the long term.

Competitor Outlook

• Guardant Health
• Exact Sciences Corporation
• NeoGenomics
• Roche Diagnostics
• Biocept
• Thermo Fisher Scientific
• Angle PLC
• F. Hoffmann-La Roche AG
• QIAGEN
• Personal Genome Diagnostics
• Sysmex Corporation
• GRAIL, Inc.
• Stilla Technologies
• OncoOne
• Epic Sciences

The competitive landscape of the liquid biopsy market is characterized by a mix of established companies and innovative startups, each aiming to capture a share of the growing demand for non-invasive cancer diagnostics. Established players such as Guardant Health and Exact Sciences Corporation are leading the market with their proprietary technologies and a strong focus on research and development. These companies have been successful in securing partnerships with healthcare providers and academic institutions to advance their liquid biopsy offerings and expand their clinical applications. Their commitment to innovation, along with robust commercialization strategies, positions them as formidable competitors in the market.

In addition to these leading companies, emerging players like GRAIL, Inc. and Epic Sciences are carving out niches with their unique approaches to liquid biopsy technology. GRAIL, known for its focus on early detection of cancer, is leveraging its advanced multi-cancer early detection tests to challenge traditional diagnostics. Meanwhile, Epic Sciences is making strides in developing CTC-based assays that offer insights into tumor biology and treatment response. Both companies exemplify the dynamic nature of the liquid biopsy market, where innovation and adaptability are key to success.

Furthermore, collaborations and partnerships across the industry are becoming increasingly common as companies seek to enhance their liquid biopsy solutions and broaden their reach. For instance, companies like Roche and Thermo Fisher Scientific are leveraging their extensive experience in diagnostics to integrate liquid biopsy technologies into their existing product lines. Such collaborations enable companies to access new markets and enhance their product offerings, ultimately benefiting patients and healthcare providers alike. As competition intensifies, the focus on delivering clinically relevant, reliable, and cost-effective liquid biopsy solutions will remain a priority for players in this evolving market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 QIAGEN
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Biocept
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 OncoOne
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Angle PLC
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 GRAIL, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 NeoGenomics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Epic Sciences
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Guardant Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Diagnostics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Sysmex Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Stilla Technologies
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 F. Hoffmann-La Roche AG
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Exact Sciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Personal Genome Diagnostics
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Liquid Biopsy Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Academic Research Centers
    • 6.1.4 Others
  • 6.2 Liquid Biopsy Market, By Application
    • 6.2.1 Early Cancer Screening
    • 6.2.2 Therapy Selection
    • 6.2.3 Treatment Monitoring
    • 6.2.4 Recurrence Monitoring
    • 6.2.5 Others
  • 6.3 Liquid Biopsy Market, By Sample Type
    • 6.3.1 Blood
    • 6.3.2 Urine
    • 6.3.3 Other Body Fluids

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Liquid Biopsy Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Liquid Biopsy market is categorized based on

By Application

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring
• Others

By Sample Type

• Blood
• Urine
• Other Body Fluids

By User

• Hospitals
• Diagnostic Laboratories
• Academic Research Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Guardant Health
• Exact Sciences Corporation
• NeoGenomics
• Roche Diagnostics
• Biocept
• Thermo Fisher Scientific
• Angle PLC
• F. Hoffmann-La Roche AG
• QIAGEN
• Personal Genome Diagnostics
• Sysmex Corporation
• GRAIL, Inc.
• Stilla Technologies
• OncoOne
• Epic Sciences